USP Tightens Supply Chain Controls with Risk-Based Vendor Qualification; Aims To Prevent New Heparin Crisis
This article was originally published in PharmAsia News
Executive Summary
The U.S. Pharmacopeia is taking a forward-looking, risk-based approach to protecting the supply chain for biological drug products from intentional and unintentional adulteration, even as it adds testing requirements aimed at preventing a new heparin crisis
You may also be interested in...
U.S. Pharmacopeial Convention Signs Pact With Chinese Regulators To Strengthen Cooperation
BEIJING - In the latest advance in a two-year drive to step up cooperation with Chinese scientists and regulators - during a series of drug and food adulteration scandals that have claimed casualties across the Pacific - the U.S. Pharmacopeial Convention has signed a new agreement with China's Center for Disease Control and Prevention
U.S. Pharmacopeial Convention Signs Pact With Chinese Regulators To Strengthen Cooperation
BEIJING - In the latest advance in a two-year drive to step up cooperation with Chinese scientists and regulators - during a series of drug and food adulteration scandals that have claimed casualties across the Pacific - the U.S. Pharmacopeial Convention has signed a new agreement with China's Center for Disease Control and Prevention
Pharmatech Associates Bikash Chatterjee And Chat Kwan On China's Shift To A Global Standard With New GMP Guidelines: An Interview With PharmAsia News
Headquartered in the San Francisco Bay Area, Pharmatech Associates provides business consulting services in the pharmaceutical, biotech and medical device manufacturing sectors. The company recently held two training programs on the new Chinese Good Manufacturing Practice guidelines in Shanghai. During its Dec. 11 training program, Bikash Chatterjee, the company's president and Chat Kwan, Pharmatech's China president, sat down with PharmAsia News' Shanghai bureau to talk about how the new Chinese GMP guidelines will affect the industry in China and abroad.